S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.72 (-3.05%)
MSFT   230.06 (-0.66%)
FB   259.18 (-1.93%)
GOOGL   2,041.00 (-2.67%)
TSLA   577.63 (-3.40%)
AMZN   3,002.00 (+0.05%)
NVDA   472.42 (-5.22%)
BABA   228.27 (-2.40%)
CGC   31.41 (+0.77%)
GE   14.20 (+4.41%)
MU   86.62 (-2.60%)
NIO   36.15 (-5.14%)
AMD   75.61 (-3.71%)
T   30.33 (+2.40%)
F   12.68 (+3.34%)
ACB   9.73 (+1.35%)
DIS   200.46 (+5.51%)
BA   227.18 (+1.77%)
NFLX   502.94 (-2.60%)
PFE   34.66 (+0.79%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.72 (-3.05%)
MSFT   230.06 (-0.66%)
FB   259.18 (-1.93%)
GOOGL   2,041.00 (-2.67%)
TSLA   577.63 (-3.40%)
AMZN   3,002.00 (+0.05%)
NVDA   472.42 (-5.22%)
BABA   228.27 (-2.40%)
CGC   31.41 (+0.77%)
GE   14.20 (+4.41%)
MU   86.62 (-2.60%)
NIO   36.15 (-5.14%)
AMD   75.61 (-3.71%)
T   30.33 (+2.40%)
F   12.68 (+3.34%)
ACB   9.73 (+1.35%)
DIS   200.46 (+5.51%)
BA   227.18 (+1.77%)
NFLX   502.94 (-2.60%)
PFE   34.66 (+0.79%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.72 (-3.05%)
MSFT   230.06 (-0.66%)
FB   259.18 (-1.93%)
GOOGL   2,041.00 (-2.67%)
TSLA   577.63 (-3.40%)
AMZN   3,002.00 (+0.05%)
NVDA   472.42 (-5.22%)
BABA   228.27 (-2.40%)
CGC   31.41 (+0.77%)
GE   14.20 (+4.41%)
MU   86.62 (-2.60%)
NIO   36.15 (-5.14%)
AMD   75.61 (-3.71%)
T   30.33 (+2.40%)
F   12.68 (+3.34%)
ACB   9.73 (+1.35%)
DIS   200.46 (+5.51%)
BA   227.18 (+1.77%)
NFLX   502.94 (-2.60%)
PFE   34.66 (+0.79%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.72 (-3.05%)
MSFT   230.06 (-0.66%)
FB   259.18 (-1.93%)
GOOGL   2,041.00 (-2.67%)
TSLA   577.63 (-3.40%)
AMZN   3,002.00 (+0.05%)
NVDA   472.42 (-5.22%)
BABA   228.27 (-2.40%)
CGC   31.41 (+0.77%)
GE   14.20 (+4.41%)
MU   86.62 (-2.60%)
NIO   36.15 (-5.14%)
AMD   75.61 (-3.71%)
T   30.33 (+2.40%)
F   12.68 (+3.34%)
ACB   9.73 (+1.35%)
DIS   200.46 (+5.51%)
BA   227.18 (+1.77%)
NFLX   502.94 (-2.60%)
PFE   34.66 (+0.79%)
Log in
NASDAQ:KLDO

Kaleido Biosciences Stock Forecast, Price & News

$9.01
+0.20 (+2.27 %)
(As of 03/8/2021 02:37 PM ET)
Add
Compare
Today's Range
$8.74
Now: $9.01▼
$9.47
50-Day Range
$8.93
MA: $11.79▼
$16.82
52-Week Range
$2.82
Now: $9.01▼
$20.50
Volume5,648 shs
Average Volume316,035 shs
Market Capitalization$382.63 million
P/E RatioN/A
Dividend YieldN/A
Beta0.02
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Kaleido Biosciences logo

Headlines

Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit
March 1, 2021 |  finance.yahoo.com
Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit
March 1, 2021 |  finance.yahoo.com
Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?
February 24, 2021 |  nasdaq.com
Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
February 12, 2021 |  marketwatch.com
Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock
February 11, 2021 |  finance.yahoo.com
What Is The Ownership Structure Like For Kaleido Biosciences, Inc. (NASDAQ:KLDO)?
February 9, 2021 |  finance.yahoo.com
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
January 20, 2021 |  finance.yahoo.com
Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
January 14, 2021 |  finance.yahoo.com
Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021 |  finance.yahoo.com
Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
January 4, 2021 |  finance.yahoo.com
Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 |  finance.yahoo.com
Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 2, 2020 |  finance.yahoo.com
Flagship Pioneering Unveils Senda Biosciences to pioneer Intersystems Biology and create novel treatments for human disease
October 30, 2020 |  prnewswire.com
Analysts Have Just Cut Their Kaleido Biosciences, Inc. (NASDAQ:KLDO) Revenue Estimates By 20%
October 23, 2020 |  finance.yahoo.com
Kaleido extends timeline for data readout on KB109 in COVID-19
October 6, 2020 |  seekingalpha.com
Kaleido Biosciences appoints Daniel Menichella as President and CEO
October 1, 2020 |  seekingalpha.com
Why Kaleido Stock Is Taking Off, And Why It Can Go Higher
September 30, 2020 |  seekingalpha.com
Dosing underway for Kaleido Biosciences's KB295 ulcerative colitis study
September 29, 2020 |  seekingalpha.com
Dosing underway in study of Kaleido Biosciences' KB295 in ulcerative colitis
September 29, 2020 |  seekingalpha.com
Top-line safety, tolerability and activity results expected in mid-2021
September 29, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KLDO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.kaleido.com
Phone617 674 9000
Employees91
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares42,467,000
Market Cap$382.63 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

2.04 out of 5 stars

Medical Sector

54th out of 1,968 stocks

Biotechnology Industry

1st out of 124 stocks

Analyst Opinion: 4.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
$9.01
+0.20 (+2.27 %)
(As of 03/8/2021 02:37 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

Is Kaleido Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kaleido Biosciences stock.
View analyst ratings for Kaleido Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Kaleido Biosciences?

Wall Street analysts have given Kaleido Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kaleido Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Kaleido Biosciences.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its quarterly earnings results on Tuesday, March, 2nd. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.16.
View Kaleido Biosciences' earnings history.

How has Kaleido Biosciences' stock been impacted by Coronavirus (COVID-19)?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have increased by 60.6% and is now trading at $8.90.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KLDO?

6 analysts have issued twelve-month target prices for Kaleido Biosciences' stock. Their forecasts range from $12.00 to $22.00. On average, they expect Kaleido Biosciences' share price to reach $17.90 in the next twelve months. This suggests a possible upside of 101.1% from the stock's current price.
View analysts' price targets for Kaleido Biosciences or view top-rated stocks among Wall Street analysts.

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 40, Pay $35k)
  • Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 42, Pay $464.81k)
  • Dr. Katharine Knobil M.D., Consultant (Age 56, Pay $668.03k)
  • Mr. Daniel L. Menichella B.A., M.B.A., Pres, CEO & Director (Age 62)
  • Mr. William E. Duke Jr., Chief Financial Officer (Age 49)
  • Dr. Johan van Hylckama Vlieg, Chief Scientific Officer
  • Ms. Susan Stewart J.D., Chief Regulatory Affairs Officer (Age 59)
  • Ms. Clare Fisher, Chief Bus. Officer

Who are some of Kaleido Biosciences' key competitors?

Some companies that are related to Kaleido Biosciences include Concordia International (CXR), PureTech Health (PRTC), iTeos Therapeutics (ITOS), Vor Biopharma (VOR), 4D Molecular Therapeutics (FDMT), Bolt Biotherapeutics (BOLT), Pharvaris (PHVS), Pharming Group (PHAR), Oxford Biomedica plc (OXB.L) (OXB), Sigilon Therapeutics (SGTX), Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Inventiva (IVA), Silence Therapeutics (SLN) and Novacyt (NCYT).
View all of KLDO's competitors.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include HarbourVest Partners LLC (5.10%), BlackRock Inc. (2.61%), Charles Schwab Investment Management Inc. (0.25%), Nuveen Asset Management LLC (0.18%), First Trust Advisors LP (0.11%) and Bank of New York Mellon Corp (0.11%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Kaleido Biosciences.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including HarbourVest Partners LLC, Charles Schwab Investment Management Inc., Barclays PLC, and First Trust Advisors LP.
View insider buying and selling activity for Kaleido Biosciences or view top insider-selling stocks.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State of Wisconsin Investment Board, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., and Citigroup Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Kaleido Biosciences or or view top insider-buying stocks.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $8.90.

How much money does Kaleido Biosciences make?

Kaleido Biosciences has a market capitalization of $377.96 million.

How many employees does Kaleido Biosciences have?

Kaleido Biosciences employs 91 workers across the globe.

What is Kaleido Biosciences' official website?

The official website for Kaleido Biosciences is www.kaleido.com.

How can I contact Kaleido Biosciences?

The company can be reached via phone at 617 674 9000.


This page was last updated on 3/8/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.